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Abstract:  A  novel  glucoconjugate  of  the  peptidic  fragment  of  cryptophycin-24  was  prepared  through  the 
replacement of the leucic acid residue with L-leucine and the functionalisation of tyrosine residue with glucose. 
Those modifications lead to a novel protected tripeptide fragment of cryptophycin-24. 
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Introduction   
 
Chemistry in the nature provides many hybrid molecules or bioconjugates that are made of 
a variety of moieties. Among the latter, peptides may be encountered as peptidoglycans and 
peptidolipids, among others. Cryptophycin-24 (Figure 1) may be considered as a macrocyclic 
hybrid that is made of two important fragments, a partially conjugated carbonyl derivative and 
a peptide moiety.  
 
Figure 1.  Cryptophycin-24 
 
An impressive work has already been performed since the first isolation of cryptophycins 
from Blue-Green Algae
1-5 and many topics have been dealt with including total synthesis
6-21, 
as  well  as  the  synthesis  of  structural  analogues  and  fragments
22-37  devoted  to  test  their 
biological activities
38-46.  Our own interest in the chemistry of peptides of biological interest
47 
prompted  us  to
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contribute to the biological activity of the compound by means of its tyrosine residue.  As a 
matter of fact, the latter has been recognised to be the most effective among amino acids for 
mediating molecular recognition
48.For this reason, we focused on the synthesis of a novel 
peptidic derivative of Cryptophycin-24 through the modification of fragments B and D.  The 
target was compound 1, shown in Scheme 1, where L-tyrosine would be O-alkylated with a 
glucose derivative (fragment B) and leucic acid would be replaced with L-Leucine methyl 
ester (fragment D).The retrosynthetic analysis of the peptidic fragment of Cryptophycin-24 
suggested that the novel hybrid could be represented by structure 2 (Scheme 1). 
 
 
Scheme 1.  Retrosynthetic analysis of target 2 
.  
The  latter  would  be  made  of  L-leucine,  -alanine  and  O-glucosylated  L-tyrosine  that 
would be used as their commercially available derivatives, namely t-butoxycarbonyl (Boc-) or 
benzyloxycarbonyl (Cbz) derivatives, except for -alanine that would beused as its methyl 
ester hydrochloride. 
We believe that the presence of a glucose residue in the target compound could result in 
adding supplementary molecular recognition properties to this compound.  As a matter of 
fact, sugars play an important role in the causative agents of infectious and bacterial diseases, 
since polysaccharides mediate host-pathogen interactions
49.  
Moreover, carbohydrates are present in many bioactive compounds
50, and they are the 
basis of many therapeutic and diagnostic strategies, thus making glycoconjugates among the 
most challenging tools to be developed to this end
51.  On the other hand, sugars are being used 
in vaccine development
52 and probes
53.  Besides, groups of investigators have shown that 
many proteins in the human glycome are involved in binding to carbohydrates, thus inducing 
glycational  modifications  of  carbohydrates  and  recognition  of  modified  sugars
54.    For 
example,  sulphated  glycosaminoglycans  are  found  on  cell  surfaces  and  within  the Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
 et al.  937 
 
 
extracellular  matrix  where  they  mediate  binding  interactions  and  provide  structural            
support
55.    At  the  same  time,  acylation  of  glycans  leads  to  highly  specific  inhibitors  of 
carbohydrate modifying transferases, and the products of acylation can play various key roles 
in human immunology, disease pathogenesis and cancer progression.  
 
Results and Discussion  
 
The novelty in this work is the functionalization of the tyrosine hydroxyl group and, to the 
best of our knowledge, such O-glucosylation of tyrosine in this class of compounds has not 
been described yet.  The synthesis of 2,3,4,6-O-acetate--D-glucopyranosyl bromide 4 was 
achieved in two steps:  first peracetylation of D-glucose was carried out with acetic anhydride 
(Ac2O) in pyridine to afford 1,2,3,4,6-penta-O-acetyl-D-glucopyranose 3 in 75% yield and 
this  latter  was  converted  into  the  corresponding  2,3,4,6-tetra-O-acetyl-D-glucopyranosyl 
bromide 4 in 98% yield using a commercial 33% HBr / CH3COOH solution according to the 
literature or with slight modifications of the protocols indicated in the cited literature
57,  58 
(Scheme 2).  Analytical data of 4 were consistent with those of the literature
58b. 
 
 
Scheme 2.  (a) pyridine, 24h, 75%; (b) HBr / CH3COOH 33%, 30 min, 98%. 
 
The  first  peptidic  synthon,  N-Boc-L-tyrosyl--alanine  methyl  ester  8  (N-Boc-L-Tyr-             
-Ala-methyl  ester)  was  synthesised  in  92%  yield  through  the  coupling  of  commercially 
available  β-alanine methyl ester hydrochloride  5  with  Boc-L-tyrosine  6  (Boc-L-Tyr)  using 
dicyclocyclohexylcarbodiimide (DCC) in the presence of hydroxybenzotriazole (HOBt) and 
triethylamine (TEA) in dichloromethane (DCM).  The reaction afforded the corresponding 
dipeptide in 92% yield.  It is useful to single out that this compound was previously described 
by Vanaman and Watt
59 and our analytical data matched quite well with theirs (Scheme 3). 
 
 
 
Scheme 3.  DCC, HOBt, TEA, CH2Cl2, RT, 24h, 92% 
 
The Cbz-analogue was synthesised in the same manner from Cbz-L-Tyrosine 6 to afford 9 
in 92%  yield.   Another approach to access  the tripeptide consisted in  coupling L-leucine 
methyl  ester  hydrochloride  10  and  Boc-β-alanine  11  using  the  experimental  conditions 
described above, so that a non-glucosylated dipeptide was generated first.  This reaction led to 
dipeptide  12  (L-leucine  methyl  ester  N-Boc--alanine),  obtained  in  88%  yield.    The 
compound displayed spectroscopic characteristics as found in the literature
60.  Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
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Removal of the Boc-group using trifluoroacetic acid (TFA) in dichloromethane afforded 
the corresponding amino derivative 13 in quantitative yield.  The latter was coupled without 
further  purification  and  under  the  same  experimental  conditions  with  Boc-L-tyrosine  to 
provide  tripeptide  14  in  85%  yield.    This  latter  represented  the  first  modification  of  the 
peptidic  fragment  of  Cryptophycin-24,  where  leucic  acid  was  replaced  with  the  L-leucyl 
methyl ester moiety (Scheme 4). 
 
 
Scheme 4.  (a) DCC, HOBt, TEA, CH2Cl2, RT, 24h, 88%; (b) TFA, CH2Cl2, 2h, 88%;              
(c) Boc-L-Tyr 5, DCC, HOBt, CH2Cl2, 24h, 85%. 
 
The second step in this work consisted of the O-alkylation of tyrosine.  It is useful to   
point out that Cbz-derivatives did not dissolve easily in the reaction media.  This necessitated 
a  slight  modification  of  the  usual  protocol  for  the  reaction  to  run  smoothly.                                 
For this purpose, Cbz derivatives needed to be previously dissolved in THF before the usual 
protocol was  implemented, i.e. reaction was  performed in  an acetone and water solution. 
2,3,4,6-Tetra-O-acetate--D-glucopyranosyl bromide 4 was used for the O-alkylating of the 
tyrosine  moiety  in  tyrosine  containing  compounds.    The  reaction  of  4  with  commercial             
Boc-Tyr-OMe  15  led  to  compound  16,  obtained  as  an  off-white  solid  in  62%  yield                
(Scheme 5).    
 
 
Scheme 5.  NaOH, acetone / H2O, 48h, 62%. 
 
The first modified dipeptides were synthesised by coupling of 4 with dipeptides 8 and 9 
under the above-described conditions.  Reaction with dipeptide 8 led to compound 17 in 79% 
yield,  whereas  dipeptide  9  afforded  the  glucoconjugate  18  in  77%  yield  (Scheme  6). 
However, because of poor water solubility of both 8 and 9, NaOH pellets were previously 
dissolved in a solution of water and acetone (v/v), and then reactions of 8 and 9 were carried 
out in this medium at room temperature.  
 
 
 Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
 et al.  939 
 
 
 
Scheme 6.  NaOH pellets in acetone / H2O (v/v), 72h, 79% for 17 and 77% for 18. 
 
Finally the initially-targeted tripeptide could be reached through the reaction of 4 with 
tripeptide  14.    The  tetraaceytate  O-glucosylated  tripeptide  2  was  isolated  in  77%  yield 
(Scheme 7).  
 
Scheme 7.  NaOH, acetone / H2O, 72h, 77%. 
 
Conclusion 
 
We have achieved a simple and affordable synthesis of a modified peptide that is to be 
involved in the synthesis of a modified cryptophycin.  The novelty of this synthesis is the 
introduction of a glucose moiety onto the tyrosine residue of the tripeptide so that the whole 
hybrid would be a frame for a compound with improved molecular recognition.  This could 
lead to improved selectivity of the biological activity of the new compound. 
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Experimental Section  
 
All the reactions with dry solvents were carried out under dry argon. NMR spectra were 
recorded in CDCl3 on a Bruker 300MHz instrument.  Chemical shifts are given in ʴ (ppm) 
and coupling constant (J) values in Hertz (Hz).  The multiplicity of signals is given as usual 
except for broad singlet that is noted br-s. GC analysis was performed on a Shimadzu 17A 
CPG chromatograph using a 30m DB-35 column.  Melting points were determined on an 
Electrothermal T1A F3.15A instrument.  Column chromatography was performed on silica 
gel 230-270 mesh (Merck) using solvents or mixtures of solvents as appropriate.  Specific Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
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rotation values were collected on Perkin Elmer Model 343 Polarimeter instrument using 0.1 
or 1g of each sample solution in an appropriate solvent. ESI-MS data were recorded in the 
positive ion  mode on a quadrupole instrument  (Waters-Micromass  ZQ).    The source and 
desolvation temperatures were kept at 120 and 250°C, respectively.  Nitrogen was used as a 
drying and nebulizing gas at flow rates of 350 and 50 L/h, respectively.  The capillary voltage 
was 3.5 kV.  The mass range was 50-1000 Da and the spectra were recorded at 1s/scan in the 
profile mode.   Calibration of the instrument  was  performed using cluster ions  of sodium 
iodide (NaI) nNa
+.  Data acquisition and processing were performed with MassLynx V4.1 
software. 
 
   2,3,4,6-Penta-O-acetyl--D-glucopyranosyl bromide 4
57,58. 
 
Methyl 3-(2-(tert-butoxycarbonyl)-3-(4-hydroxyphenyl)propanamido)propanoate 8 
N-Boc-L-tyrosine  6  (2g,  7.11mmol)  and  -alanine  hydrochloride  methyl  ester  5  (992mg, 
7.11mmol) (Aldrich) were dissolved in DCM (10 mL).  Then triethylamine (TEA) (4.94 mL, 
35.55  mmol)  and  hydroxybenzotriazole  (HOBt)  (1.06  g,  7.82  mmol)  were  added  to  the 
solution.  Stirring was kept for 10 min at 0°C, and then dicyclohexylcarbodiimide (DCC) 
(1.61 g, 7.82 mmol.) was added. The mixture was kept at 0°C for 30 min and then left at room 
temperature for 10h.  After filtration with suction and removal of the solvent, the residue was 
dissolved in ethyl acetate (AcOEt) (10 mL) and filtered off once again.  The organic layer was 
then washed successively with a 5% aqueous citric acid solution (10 mL), brine (10 mL),       
a 5% aqueous solution of potassium carbonate and finally with water (10 mL).  
Finally, it was dried over anhydrous MgSO4, filtered and the solvent was removed under 
reduced pressure.  The residue was purified on a silicagel column using DCM-MeOH (98:2). 
After removal of the solvents, the final product was recrystallized in AcOEt to afford 2.28 g 
of off-white crystals (92%); mp 104-106°C; [ʱ]
22
D +66.2°, c = 1 in CHCl3.  MS/LMRS [ESI]
+ 
m/z calcd (for C18H26N2NaO6): m/z =389.17, found 389.1.  
1H NMR (300 MHz, CDCl3)  
(ppm): 1.42 (s, 9H, t-Bu), 2.41 (t, 5.5 Hz, 2H, CH2COO), 2.92 (d, 6.7 Hz, 2H, CH2CHCO), 
3.42 (t, 5.5 Hz, 2H, CH2N), 3.77 (s, 3H, OCH3), 5.30 (t, 5.6 Hz, 1H, CHNH), 6.33 (t, 6.3 Hz, 
1H, NH), 6.88 (d, 9 Hz, 2H, Ph), 7.01(d, 9 Hz, 2H, Ph), 7.60 (br-s, 1H, OH).
13C NMR (300 
MHz, CDCl3)   28.3 (3C), 33.6, 34.7, 38.0, 51.8, 56.2, 80.0, 115.6 (2C), 130.4 (2C), 132.1, 
154.3, 155.9, 171.2, 172.6. 
Methyl 3-(2-(benzyloxycarbonyl)-3-(4-hydroxyphenyl)propanamido)propanoate 9 
N-CBz-L-tyrosine 7 (1g, 3.17 mmol) and -alanine methyl ester hydrochloride 5 (442 mg, 
3.17  mmol)  were  dissolved  in  DCM  (10  mL);  then  TEA  (2.2ml,  15.85mmol)  and  HOBt 
(0.47g, 3.487 mmol) were added to the solution.  After stirring for 10 min at 0°C, DCC 
(0.72g, 3.487 mmol) was added to the mixture, and the latter was stirred for 30 min under the 
same conditions and then left at room temperature for 10 h.  After filtration with suction and 
concentration, the resulting residue was dissolved in ethyl acetate and filtered off once again. 
The  resulting  filtrate  was  washed  successively  with  a  5%  aqueous  citric  acid  solution             
(10 mL), brine (10 mL), 5% aqueous potassium carbonate solution (10 mL) and finally with 
water (10 mL).  The organic layer was separated and then dried over anhydrous magnesium 
sulphate (MgSO
4) filtered and concentrated under diminished pressure.  The resulting residue 
crystallized  in  ether  to  afford  9  as  an  off-white  product  (1.17  g,  92%).    mp  133°C;                   
[ʱ]
22
D  +78.1°,  c  = 1  in  CHCl3.   
1H  NMR  (300  MHz,  DMSO)  ;  ʴ  2.41  (t,  5.6  Hz,  2H, Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
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CH2COOMe), 2.80 (d, 6.7 Hz, 2H, CH2CHNH), 3.43 (t, 5.6 Hz, 2H, CH2NH), 3.6 (3H, s, 
OCH3), 4.10 (br-s, 1H, NH), 4.90 (t, 5.6 Hz, 1H, CHNH), 5.00 (d, 7,2 Hz, 2H, CH2Ph), 6.77 
(d, 9 Hz, 2H, Ph), 7.00 (d, 9.0 Hz, 2H, Ph), 7.32 (m, 5H, Ph), 8.11 (br-s, 1H,NH), 9.20 (br-s, 
1H, OH).  
13C NMR (300 MHz, DMSO)  35.3, 36.3, 37.5, 51.8, 55.2, 66.1, 115.8 (2C), 
127.7  (2C),  127.6,  128.9  (2C),  129.2  (2C),  132.1,  141.6,  155.8,  156.0,  170.9,  171.4. 
MS/LMRS [ESI]
+ m/z calcd (for C21H24N2NaO6): m/z = 423.15, found 422.9. 
(S)-Methyl 2-(3-(tert-butoxycarbonyl)propanamido)-4-methylpentanoate 12 
N-Boc--alanine 11 (2g, 10.57 mmol) and L-leucine methyl ester chlorhydrate 10 (1.92 g, 
10.6  mmol) were dissolved DCM  (10 mL), followed by TEA (7.34 ml, 52.88mmol) and 
HOBt (1.57 g, 11.6 mmol).  After stirring for 10 min at 0°C, DCC (2.4 g, 11.63 mmol) was 
added.  The mixture was left at room temperature for 10 min and then at room temperature for 
10h.    The  mixture  was  then  filtered  under  suction  and  the  filtrate  was  evaporated  under 
reduced pressure.  The remaining residue was dissolved in ethyl acetate (10 mL) and then 
filtered again.  The resulting filtrate was washed successively with a 5% aqueous citric acid 
solution (10 mL), brine (10 mL), 5% aqueous potassium carbonate solution (10 mL) and then 
with water (10 mL).  Finally it was dried over anhydrous MgSO
4, filtered off and the solvent 
removed under reduced pressure to afford a residue that was purified on silicagel column 
using DCM-methanol (95/5).  The resulting solid was recrystallised in water to afford 12 as 
an off-white product (3.53 g, 88%). Mp = 50-52°C. [ʱ]
22
D +7.5°, c = 0.1 in CHCl3. 
1H NMR 
(300  MHz,  CDCl3)  ʴ  0.95  (d,  6.0  Hz,  6H,  CH3-Bu-i),  1.43  (s,  9H,  t-Bu),  1.54  (m,  1H,                
CH-Bu-i), 1.64 (m, 2H, CH2-Bu-i), 2.44 (m, 2H, CH2CH2NBoc), 3.43 (m, 2H, CH2NBoc), 
3.74  (s,  3H,  OCH3),  4.77  (m,  1H,  (CHCO2),  5.22  (br-s,  1H,  β-Ala-  NH),  5.99(br-s,  1H,             
Leu-NH).  
13C NMR (125 MHz, CDCl3) ʴ 21.9, 22.8, 24.9, 28.4, 36.3, 36.7, 41.6, 50.7, 52.3, 
77.2, 156.2, 171.5, 173.5.  MS/LMRS [ESI]
+ m/z calcd (for C15H28N2NaO5): m/z = 339.19, 
found 339.1. 
(S)-Methyl 2-(3-aminopropanamido)-4-methylpentanoate 13 
A solution of  (S)-Methyl 2-(3-(tert-butoxycarbonyl)propanamido)-4-methylpentanoate 12  
(2 g, 6.32 mmol) in DCM (22.6 mL) was treated with trifluoroacetic acid (TFA) (52.66 mL) 
at 0 °C then stirred at room temperature for 2 h.  The resulting mixture was concentrated and 
dried  in  vacuo.    The  crude  product  13  (2.36  g,  TFA  salt)  was  used  directly  in  the  next 
reaction, without further purification. 
(S)-Methyl 2-(3-aminopropanamido)-4-methylpentanoate 14 
Boc-L-tyrosine (1.78 g 6.32 mmol) and 13 (2.36 g 6.32 mmol) were dissolved in DCM 
(10 mL).  Then HOBt (0.94 g, 6.95 mmol) was added to the solution.  After 10 min stirring         
at 0 °C, DCC (1.43 g, 6.95 mmol) was added, and the mixture was stirred at this temperature 
for 30 min, and then kept at room temperature for 10 h.  After filtration with suction and 
concentration, the resulting residue was dissolved in ethyl acetate and filtered off once again. 
The  resulting  filtrate  was  washed  successively  with  a  5%  aqueous  citric  acid  solution          
(10 mL), brine (10 mL), 5% aqueous potassium carbonate solution(10 mL) and then with 
water (10 mL).  Finally it was dried over anhydrous MgSO
4, filtered off and the solvent 
removed under reduced pressure to afford a residue that was purified on silicagel column 
using DCM-MeOH (from 98:2 to 90:10) to afford 14 as an off-white solid (2.58g, 85%). 
MS/LMRS [ESI]
+ m/z calcd (for C24H37N3NaO7): m/z = 502.25, found 502.22. Mp = 120°C; 
[ʱ]
22
D +58.3°, c = 1 in CHCl3. 
1H NMR (300 MHz, CDCl3) ʴ 0.96 (d, 6 Hz, 6H, CH3-Bu-i), 
1.42 (s, 9H, t-Bu), 1.55 (m, 1H, CH(CH3)2), 1.71 (m, 2H,CH2 CH(CH3)2), 2.4 (t, 5.5 Hz, 2H, Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
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CH2CON), 2.92 (d, 6.7 Hz, 2H, CH2CHNHCO), 3.11 (br-s, 1H, NH), 3.55 (m, 2H, CH2NH), 
3.88  (s,  3H,  OMe),  3.8  (br-s,  1H,  NH),  4.62  (m,  1H,  CHCO2Me),  5.20  (t,  5.6  Hz,  1H, 
CHNHCOBoc), 6.88 (d, 9 Hz, 2H, Ph), 7.00 (br-s, 1H, NH), 7.2 (br-s, 1H, OH), 7.0 (d, 9 Hz, 
2H, Ph),.
13C NMR (75 MHz, CDCl3)  21.3, 22.9, 24.9, 28.3 (3C), 36.6, 36.9, 37.2, 39.8, 
51.4, 52.6, 56.8, 80.3, 115.6 (2C), 130.4 (2C), 130.5, 135.4, 155.9, 172.5, 173.0, 174.9.  
2,3,4,6-Tetra-O- acetyl--D-glucopyranosyl-L-tyrosine methyl ester 16 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl  bromide 4  (2.0  g,  4.86  mmol),  N-Boc-tyr-
OMe  15 (2.153g, 7.29mmol),  pellets  of  sodium  hydroxide  (291 mg, 7.29 mmol), water            
(15 ml) and acetone (15 ml) were mixed together, and the mixture was stirred for 48 h.  Then, 
the  mixture  was  purified  on  a  silicagel  column  using  ethyl  acetate-cyclohexane  (8/2). 
Concentration of the eluate afforded a solid that was recrystallised in ethyl acetate to provide 
16 as an off-white solid (1.89 g, 62%).  Mp 165°C; [ʱ]
22
D -33.6°, c = 1 in MeOH. MS/LMRS 
[ESI]
+ m/z calcd (for C29H39NNaO14): m/z =  648.23, found 648.30.
    1H NMR (300 MHz, 
DMSO)  ʴ 
1H  NMR  (300  MHz,  DMSO)  ʴ  1.33  (s,  9H,  t-Bu),  2.02  (s,  3H,  OC(O)CH3),               
2.03 (s, 3H, OC(O)CH3), 2.11(s, 3H, OC(O)CH3),  2.22 (s, 3H, OC(O)CH3),  2.92 (d, 6.7 Hz, 
2H,  CH2Ph),  3.65  (s,  3H,  OMe),  4.11  (m,  1H,  CHOC(O)CH3),  4.21  (m,  2H,  CH2OAc),                
5.01  (m,  2H,  CHCH2OC(O)CH3,  CHNHBoc),  5.22  (d,  7.2  Hz,  1H,  CHOC(O)CH3),               
5.33  (m,  1H,  CHOC(O)CH3),  5.88  (d,  10  Hz,  1H,  OCHOPh),  6.61  (d,  9  Hz,  2H,  Ph),                     
6.95 (d, 9 Hz, 2H, Ph).  
13C NMR (300 MHz, DMSO).  (ppm) 20.6, 20.7, 20.7, 21.0, 28.3 
(3C), 36.8, 51.4, 52.6, 61.6, 68.0, 69.4, 69.9, 70.0, 89.3, 98.2, 115.4 (2C), 130.2 (2C), 130.7, 
154.2, 155.8, 169.9, 169.9, 170.0, 170.5, 171.4.
 
2,3,4,6-Tetra-O- acetyl--D-glucopyranosyl-N-Boc-L-tyrosyl--alanine methyl     
ester 17 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl bromide 4 (1.51 g, 3.67 mmol), compound 7 
(1.615 g,4.4 mmol), NaOH (176 mg, 4.4 mmol), water (10 ml) and acetone (10 ml) were 
mixed  and  stirred  at  room  temperature  for  72h.    Column  chromatography  using  AcOEt- 
cyclohexane (7:3) afforded 17 as an off-white solid after removal of the solvents (2.02 g, 
79%).    Mp  218°C.  [ʱ]
22
D  +32.6°,  c  = 1  in  MeOH.    MS/LMRS  [ESI]
+  m/z  calcd  for 
C32H44N2NaO15): m/z =719.26, found 719.30.  
1H NMR (300 MHz, DMSO) ʴ 1.33 (s, 9H, t-Bu), 2.01 (s, 3H, OC(O)CH3), 2.0 (s, 3H, 
OC(O)CH3), 2.11 (s, 3H, OC(O)CH3), 2.11 (s, 3H, OC(O)CH3),  2.41 (m, 2H, CH2COOMe), 
2.80 (d, 6.7 Hz, 2H, CH2CHNH), 3.40 (m, 2H, CH2NH), 3.77 (s, 3H, OCH3), 4.01 (m, 1H, 
CHOC(O)CH3), 4.11 (m, 2H, CH2OC(O)CH3), 5.11 (m, 2H, CHCH2Ph, CHCH2OC(O)CH3), 
5.22  (d,  7.2  Hz,  1H,  CHOC(O)CH3),  5.2  (m,  1H,  CHOC(O)CH3),  5.55  (d,  10  Hz,  1H, 
OCHOPh), 6.77 (d, 9 Hz, 2H, Ph), 6.88 (brs, 1H, NH), 6.98 (d, 9 Hz, 2H, Ph), 7.92  (br-s, 1H, 
NH). 
13C NMR (300 MHz, DMSO)  20.5, 20.7, 20.8, 21.1, 28.3 (3C), 33.8, 36.7, 38.2, 51.8, 
56.3, 61.6, 68.1, 69.4, 69.9, 70.0, 79.8, 98.3, 115.5 (2C), 130.0 (2C), 130.7, 154.3, 155.9, 
169.9, 169.9, 170.1, 170.5, 171.3, 172.7. 
2,3,4,6-Tetra-O- acetyl--D-glucopyranosyl-N-Cbz-L-tyrosyl--alanine methyl    
ester 18 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl bromide 4 (1g, 2.43 mmol) ; 9 (1.46 g, 3.65 
mmol) ; NaOH pellets (146 mg, 3.65 mmol) were dissolved in a solution  of acetone/water 
(10 ml v/v (6-4).  Then 9 was added and stirred until full dissolution. Afterwards, 4 was 
added, and the mixture was stirred for 72h at room temperature.  After removal of solvents, 
the  residue  was  purified  on  a  Silicagel  column  chromatography  using  ethyl  acetate-Mediterr.J.Chem., 2014, 3(4),  A.  Mezrai
 et al.  943 
 
 
cyclohexane-AcOEt (7:3) to afford 18 as an off-white solid after removal of the solvents  
(1.77 g, 77%).   mp  =  134°C. [ʱ]
22
D  -17.2°,  c  = 1 in  MeOH. MS/LMRS [ESI]
+m/z  calcd            
(for C35H42N2NaO15): m/z =753.25, found 753.40.  
1H NMR (300 MHz, CDCl3) ʴ  2.02 (s, 3H, OC(O)CH3), 2.0 (s, 3H, OC(O)CH3), 2.10 (s, 3H, 
OC(O)CH3), 2.11 (s, 3H, OC(O)CH3), 2.43 (t, 5.6 Hz, 2H, CH2COOMe), 2.8 (d, 6.7 Hz, 2H, 
CH2CHNH), 3.42 (t, 5.6 Hz, 2H, CH2NH), 3.77 (s, 3H, OCH3), 4.00 (m, 1H, CHOC(O)CH3), 
4.11 (m, 2H, CH2CHOC(O)CH3),  4.96 (t, 5.6 Hz,1H, CHNH), 5.11 (m, 2H, CHOC(O)CH3), 
5.22 (d, 2H, 5.6 Hz, CH2Ph), 5.24 (m, 1H, CHOC(O)CH3), 6.2 (d, 10 Hz, 1H, OCHOPh), 
6.87(d, 9.0 Hz, 2H, Ph), 6.80 (br s, 1H, NH), 6.95 (d, 9.0 Hz, 2H, Ph), 7.00 (br-s, 1H, NH). 
7.23 (m, 5H, Ph).
13C NMR (300 MHz, CDCl3)   20.6, 2.7, 20.7, 21.0, 33.9, 34.8, 38.1, 51.8, 
56.4, 60.4, 63.4, 67.0, 67.8, 70.4, 72.5, 92.0, 115.7, 117.3, 128.0 (2C), 128.2, 128.5 (2C), 
130.4 2C), 135.5, 139.3, 155.3, 155.9, 169.5, 169.8, 169.9, 170.1, 170.7, 171.2. 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-N-Cbz-L-tyrosyl--alanyl-L-leucine 
methyl ester 2 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl bromide 4 (755 mg, 1.84 mmol), 14 (1.06g, 
2.21 mmol),  NaOH (88.4 mg, 2.21 mmol), water (10 mL) and acetone (10 mL) were mixed 
and stirred for 72 h. Silica gel column chromatography using ethyl acetate-cyclohexane (8/2) 
afforded 2 as an off-white solid after removal of solvents (1.14 g, 77%).  mp = 108.5°C.  
[ʱ]
22
D -14.2°, c = 1 in MeOH.  MS/LMRS [ESI]
+m/z calcd(for C38H55N3NaO16): m/z =832.35, 
found 832.51. 
1H NMR (300 MHz, DMSO) ʴ 0.96 (d, 6 Hz, 6H, CH3i-Bu), 1.32 (s, 9H, t-Bu), 
1.55 (m, 1H, CH(CH3)2), 1.71 (m, 2H,CH2 CH(CH3)2), 2.01 (s, 3H, OC(O)CH3), 2.0 (s, 3H, 
OC(O)CH3),  2.105  (s,  3H,  OC(O)CH3),  2.11  (s,  3H,  OC(O)CH3),  2.4  (t,  5.5  Hz,  2H, 
CH2CON), 2.80 (d, 6.7 Hz, 2H, CH2CHCON), 3.62 (s, 3H, OMe), 3.55 (m, 2H, CH2NH), 
4.01 (m, 1H, CHOC(O)CH3), 4.11 (m, 2H, CH2OAc), 4.33 (m, 1H, CHCO2Me), 5.10 (m, 2H, 
CHOC(O)CH3,  CHOC(O)CH3),  5.33  (m,  1H,  CHOC(O)CH3),  5.44  (t,  5.6  Hz,  1H, 
CHNHCOBoc), 6.77 (d, 9 Hz, 2H, Ph), 5.50 (d, 1H, 10 Hz, OCHOPh), 6.88 (br-s, 1H, NH), 
7.00 (d, 9 Hz, 2H, Ph), 7.90 (br-s, 1H, NH), 8.30 (br-s, 1H, NH). 
13C NMR (300 MHz, 
DMSO) ʴ 20.5, 20.8, 20.9, 21.1, 21.8, 23.2, 24.96, 28.62 (3C), 35.6, 37.0, 39.2, 39.5, 50.7, 
52.3, 56.5, 68.2, 69.4, 69.9 70.0, 71.2, 78.7, 98.3, 115.5 (2C), 128.6, 130.5 (2C), 155.6, 166.4, 
169.8, 169.9, 170.1, 170.5, 171.1, 172.2, 173.6. 
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